Ecopetrol
EC
Meta Platforms
META
MARA Holdings
MARA
Salesforce
CRM
Oracle
ORCL
US Stock MarketDetailed Quotes
CLLS Cellectis
- 1.600
- +0.070+4.58%
Trading Jan 23 15:16 ET
160.15MMarket Cap-1.37P/E (TTM)
1.650High1.520Low241.16KVolume1.540Open1.530Pre Close379.20KTurnover0.34%Turnover RatioLossP/E (Static)100.09MShares3.38052wk High1.24P/B114.34MFloat Cap1.41052wk Low--Dividend TTM71.46MShs Float50.000Historical High--Div YieldTTM8.50%Amplitude0.963Historical Low1.572Avg Price1Lot Size
About Cellectis Company
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Company Profile
SymbolCLLS
Company NameCellectis
Listing DateMar 25, 2015
Issue Price36.83
Founded1999
CEODr. Andre Choulika
MarketNASDAQ
Employees221
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
Address8, rue de la Croix Jarry
CityParis
ProvinceIle-de-France
CountryFrance
Zip Code75013
Phone33-1-81-69-16-00
Websitehttp://www.cellectis.com
Company Executives
- Name
- Position
- Salary
- Dr. Andre Choulika
- Director and Chief Executive Officer
- 1.13M
- Dr. David Sourdive
- Director, Deputy Chief Executive Officer and Executive Vice President, CMC and Manufacturing
- 657.84K
- Arthur Stril
- Chief Business Officer
- --
- Bing Wang, PhD
- Chief Financial Officer
- --
- Philippe Duchateau, PhD
- Chief Scientific Officer
- --
- Dr. Mark Frattini, M.D.,PhD
- Chief Medical Officer
- --
- Kyung Nam-Wortman
- Executive Vice President and Chief Human Resources Officer
- --
- Stephan Reynier
- Chief Regulatory and Pharmaceutical Compliance Officer
- --
- Dr. Steven Doares, PhD
- Senior Vice President, US Manufacturing
- --
- Dr. Jean-Pierre Garnier, PhD
- Chairman of the Board
- 203.80K
- Laurent Arthaud
- Director
- --
- Pierre Tristan Michel Bastid
- Independent Director
- 97.34K
- Axel-Sven Malkomes
- Independent Director
- 102.75K
- Rainer J. Boehm, M.B.A.
- Independent Director
- 99.60K
- Dr. Donald A. Bergstrom, M.D.,PhD
- Independent Director
- 102.75K
- Cecile Chartier
- Independent Director
- 47.77K
- Marie-Bleuenn Terrier
- General Counsel
- --
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.